Jim Cramer on Danaher: “This Could Be the First Truly Strong Quarter in Years”

Core Insights - Danaher Corporation is expected to report positive quarterly earnings, with significant orders from biotech companies indicating a potential turnaround after a prolonged period of underperformance [1] - The stock has shown a notable recovery, increasing 31% from its April low and 25% from its September low, driven by strong growth in the bioprocessing division [2] - Wall Street anticipates that Danaher will achieve its best growth in years in 2026, with mid-single-digit revenue growth and high single-digit earnings growth projected [2] Company Overview - Danaher Corporation specializes in instruments, consumables, software, and services for bioprocessing, life sciences research, and clinical diagnostics [2] - The company has shifted focus towards life sciences diagnostics after spinning off its water and product quality testing business, Veralto [2] Recent Performance - In late October, Danaher reported a strong quarter with a small revenue beat and 3% organic growth, alongside a significant earnings beat [2] - Despite previous frustrations with stock performance, recent results have led to a positive outlook and increased stock movement [2]